Regulatory Watch
June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022 June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022

Disclosures & Ethics

You deserve to know how we make money and how we keep our analysis honest. Here's everything, plainly stated.

How We Make Money

PeptideExaminer earns revenue through two channels:

Display Advertising: We run standard display ads through advertising networks. Advertisers do not influence our editorial content. We do not accept ad placements from peptide vendors.

Affiliate Links: Some articles contain links to peptide vendors. When you purchase through these links, we may earn a commission at no additional cost to you. These links are always clearly marked with a disclosure notice.

What We Don't Do

No pay-for-play reviews. Vendors cannot purchase favorable coverage. Our vendor ratings are determined by our methodology and cannot be influenced by payment.

No pre-publication review. Vendors do not see our articles before publication. We may contact vendors for comment as part of our research process, but they have no editorial control over the final content.

No sponsored content. Every article on PeptideExaminer is written by our editorial team based on independent research. We do not publish content written or commissioned by vendors.

No newsletter monetization. Our email newsletter contains no affiliate links and no sponsored content. It's a free, clean briefing. Affiliate links exist only on our website articles where they're clearly disclosed.

Editorial Independence Policy

Our editorial and revenue operations are completely separated. The people who write and rate vendors have no involvement in affiliate partnerships. The existence of an affiliate relationship with a vendor does not affect that vendor's rating — positively or negatively.

We regularly recommend against popular products and have given low ratings to vendors with whom we have affiliate relationships when our analysis warranted it.

Corrections Policy

If we get something wrong, we fix it publicly. Corrections are noted at the top of the affected article with an explanation of what changed and why. We don't quietly edit published content.

Medical Disclaimer

PeptideExaminer provides educational content about peptide research, market analysis, and vendor evaluation. Nothing on this site constitutes medical advice. Always consult a qualified healthcare provider before using any peptide product.

Contact

Questions about our editorial policies? Concerns about accuracy? Reach us at ethics@peptideexaminer.com.